The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus

Nature Immunology

Volumn 14, Issue 12, 2013, Pages 1266-1276

  Keating, Rachael ^a   Hertz, Tomer ^b   Wehenkel, Marie ^a   Harris, Tarsha L ^a   Edwards, Benjamin A ^a   McClaren, Jennifer L ^a   Brown, Scott A ^a   Surman, Sherri ^a   Wilson, Zachary S ^b   Bradley, Philip ^b   Hurwitz, Julia ^a   Chi, Hongbo ^a   Doherty, Peter C ^a   Thomas, Paul G ^a   McGargill, Maureen A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INFLUENZA VIRUS HEMAGGLUTININ; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CONTROLLED STUDY; CROSS PROTECTION; FEMALE; GERMINAL CENTER; IMMUNOMODULATION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INHIBITION KINETICS; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; B-LYMPHOCYTES; CELL LINE; FEMALE; FLOW CYTOMETRY; HOST-PATHOGEN INTERACTIONS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; SIROLIMUS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES;

EID: 84887976550     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2741     Document Type: Article

References (48)

1. Osterholm, M.T. & Kelley, N.S. Mammalian-transmissible H5N1 influenza: facts and perspective. mBio 3, e00045-12 (2012).
2. Herfst, S. et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336, 1534-1541 (2012).
3. Imai, M. et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486, 420-428 (2012).
4. Pica, N. & Palese, P. Toward a universal influenza virus vaccine: prospects and challenges. Annu. Rev. Med. 64, 189-202 (2013).
5. Thomas, P.G., Keating, R., Hulse-Post, D.J. & Doherty, P.C. Cell-mediated protection in influenza infection. Emerg. Infect. Dis. 12, 48-54 (2006). (Pubitemid 43143535)
6. Okuno, Y., Isegawa, Y., Sasao, F. & Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67, 2552-2558 (1993). (Pubitemid 23118850)
7. Throsby, M. et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 eecovered from human IgM+ memory B cells. PLoS ONE 3, e3942 (2008).
8. Ekiert, D.C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526-532 (2012).
9. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
10. Corti, D. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663-1673 (2010).
11. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
12. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193 (2011).
13. Corti, D. & Lanzavecchia, A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31, 705-742 (2013).
14. Powell, J.D., Pollizzi, K.N., Heikamp, E.B. & Horton, M.R. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30, 39-68 (2012).
15. Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108-112 (2009).
16. Pearce, E.L. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103-107 (2009).
17. Turner, A.P. et al. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am. J. Transplant. 11, 613-618 (2011).
18. Wang, Y., Wang, X.-Y., Subjeck, J.R., Shrikant, P.A. & Kim, H.L. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br. J. Cancer 104, 643-652 (2011).
19. Rao, R.R., Li, Q., Odunsi, K. & Shrikant, P.A. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 32, 67-78 (2010).
20. Klenk, H.D. & Garten, W. Host cell proteases controlling virus pathogenicity. Trends Microbiol. 2, 39-43 (1994). (Pubitemid 24051419)
21. Venturi, V., Davenport, M.P., Swan, N.G., Doherty, P.C. & Kedzierska, K. Consequences of suboptimal priming are apparent for low-avidity T-cell responses. Immunol. Cell Biol. 90, 216-223 (2012).
22. Rutigliano, J.A. et al. Protective memory responses are modulated by priming events prior to challenge. J. Virol. 84, 1047-1056 (2010).
23. Huber, V.C., Thomas, P.G. & McCullers, J.A. A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 27, 1192-1200 (2009).
24. Belser, J.A. et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 501, 556-559 (2013).
25. Watanabe, T. et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501, 551-555 (2013).
26. Zhou, J. et al. Biological features of novel avian influenza A (H7N9) virus. Nature 499, 500-503 (2013).
27. Thomas, P.G. et al. Hidden epitopes emerge in secondary influenza virus-specific CD8+ T cell responses. J. Immunol. 178, 3091-3098 (2007). (Pubitemid 46333190)
28. Khurana, S., Frasca, D., Blomberg, B. & Golding, H. AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. PLoS Pathog. 8, e1002920 (2012).
29. Victora, G.D. & Nussenzweig, M.C. Germinal centers. Annu. Rev. Immunol. 30, 429-457 (2012).
30. Muramatsu, M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563 (2000).
31. Feng, J.Q., Mozdzanowska, K. & Gerhard, W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J. Virol. 76, 1369-1378 (2002). (Pubitemid 34066439)
32. Verbonitz, M.W., Ennis, F.A., Hicks, J.T. & Albrecht, P. Hemagglutinin-specific complement-dependent cytolytic antibody response to influenza infection. J. Exp. Med. 147, 265-270 (1978). (Pubitemid 8250823)
33. Huber, V.C., Lynch, J.M., Bucher, D.J., Le, J. & Metzger, D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166, 7381-7388 (2001). (Pubitemid 32525614)
34. Hashimoto, G., Wright, P.F. & Karzon, D.T. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J. Infect. Dis. 148, 785-794 (1983). (Pubitemid 14244263)
35. Jegaskanda, S. et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190, 1837-1848 (2013).
36. Nimmerjahn, F. & Ravetch, J.V. Fc? receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
37. Limon, J.J. & Fruman, D.A. Akt and mTOR in B cell activation and differentiation. Front. Immunol. 3, 228 (2012).
38. Allen, C.D.C. et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. 5, 943-952 (2004). (Pubitemid 39276239)
39. Zhang, S. et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood 117, 1228-1238 (2011).
40. Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621-663 (2011).
41. Hoffmann, E., Krauss, S., Perez, D., Webby, R. & Webster, R.G. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20, 3165-3170 (2002).
42. Andreansky, S.S. et al. Consequences of immunodominant epitope deletion for minor influenza virus-specific CD8+-T-cell responses. J. Virol. 79, 4329-4339 (2005). (Pubitemid 40388370)
43. Hilpert, K., Winkler, D.F.H. & Hancock, R.E.W. Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion. Nat. Protoc. 2, 1333-1349 (2007). (Pubitemid 46952315)
44. Winkler, D.F.H., Hilpert, K., Brandt, O. & Hancock, R.E.W. Synthesis of peptide arrays using SPOT-technology and the CelluSpots-method. Methods Mol. Biol. 570, 157-174 (2009).
45. Duda, R.O., Hart, P.E. & Stork, D.G. Pattern Classification (Wiley-Interscience, 2000).
46. Leaver-Fay, A. et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545-574 (2011).
47. Pone, E.J. et al. BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-?B pathway. Nat. Commun. 3, 767 (2012).
48. Hoffmann, E., Lipatov, A.S., Webby, R.J., Govorkova, E.A. & Webster, R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc. Natl. Acad. Sci. USA 102, 12915-12920 (2005). (Pubitemid 41279464)